<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00415701</url>
  </required_header>
  <id_info>
    <org_study_id>DINA-KEK7406-IBAN-2006-1</org_study_id>
    <nct_id>NCT00415701</nct_id>
  </id_info>
  <brief_title>Effect of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery</brief_title>
  <official_title>Effect of an Anesthetic Induction Dose of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of a single dose of etomidate for
      patients undergoing cardiac surgery with the use of cardiopulmonary bypass (CPB) on post-CPB
      adrenocortical responsiveness, on requirements of hemodynamic support, and on use of
      intensive care resources.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of absolute and relative adrenal insufficiency</measure>
    <time_frame>Preoperative day to postoperative day (POD) 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative requirements of vasoactive drugs during surgery and in the intensive care unit (ICU)</measure>
    <time_frame>Induction of anesthesia to POD 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of failure to wean off cardiopulmonary bypass on first intention</measure>
    <time_frame>intraoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lactate</measure>
    <time_frame>Induction of anesthesia to discharge ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to extubation</measure>
    <time_frame>Induction of anesthesia to extubation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay (LOS) in the intensive care unit (ICU), intermediate care unit (IMC), and hospital</measure>
    <time_frame>Admission to discharge: ICU, IMC, and hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of results with preoperative risk, stress-dose hydrocortisone replacement, type of surgery</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Mitral Valve Regurgitation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etomidate as a single induction dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol as a single induction dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hydrocortisone substitution or placebo (50-50%) in etomidate-group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etomidate</intervention_name>
    <description>Single induction dose of etomidate 0.2%; total dose 0.15 mg/kg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Single induction dose of propofol 2%; total dose 1.5 mg/kg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Hydrocortisone 100 mg/2 ml: day of operation 3x, POD 1 2x, POD 2 1x</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 0.9%</intervention_name>
    <description>NaCl 0.9% 2 ml; day of operation 3x, POD 1 2x, POD 2 1x</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tetracosactin</intervention_name>
    <description>Diagnostic test, Tetracosactin 250 microg iv</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients undergoing elective

               -  coronary artery bypass graft (primary or re-operation)

               -  mitral valve reconstruction/replacement for mitral valve regurgitation

          -  Age between 18 and 80 years (extremes included)

          -  Subject itself has signed the informed consent

          -  No clinically relevant deviation from the laboratory's reference range of
             biochemistry, hematology, or urinalysis testing

        Exclusion Criteria:

          -  Participation in another ongoing interventional trial

          -  Known adrenocortical insufficiency

          -  Use of etomidate or propofol within 1 week preoperatively

          -  Use of glucocorticoids within 6 month preoperatively

          -  Known sensitivity to etomidate, propofol, or emulgator

          -  Severe hepatic dysfunction (bilirubin &gt; 3mg/dl)

          -  Severe renal dysfunction (plasma creatinine &gt; 180mikromol/l)

          -  Sepsis, endocarditis or other chronic inflammatory disease

          -  Manifest insulin-dependent diabetes mellitus

          -  Positive HIV serology

          -  Hemodynamically significant carotid stenosis requiring treatment

          -  Serious illnesses: endocrine, neurological, psychiatric, metabolic disturbances

          -  Pregnancy or breast-feeding female; females will be subject to pregnancy testing

          -  Requirement of rapid sequence induction

          -  Emergency surgery

          -  History of asthma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan M Jakob, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Inselspital, Berne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departments of Intensive Care Medicine and Anesthesiology</name>
      <address>
        <city>Bern</city>
        <state>BE</state>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Malerba G, Romano-Girard F, Cravoisy A, Dousset B, Nace L, Lévy B, Bollaert PE. Risk factors of relative adrenocortical deficiency in intensive care patients needing mechanical ventilation. Intensive Care Med. 2005 Mar;31(3):388-92. Epub 2005 Feb 10.</citation>
    <PMID>15703896</PMID>
  </reference>
  <reference>
    <citation>Weis F, Kilger E, Roozendaal B, de Quervain DJ, Lamm P, Schmidt M, Schmölz M, Briegel J, Schelling G. Stress doses of hydrocortisone reduce chronic stress symptoms and improve health-related quality of life in high-risk patients after cardiac surgery: a randomized study. J Thorac Cardiovasc Surg. 2006 Feb;131(2):277-82.</citation>
    <PMID>16434254</PMID>
  </reference>
  <reference>
    <citation>den Brinker M, Joosten KF, Liem O, de Jong FH, Hop WC, Hazelzet JA, van Dijk M, Hokken-Koelega AC. Adrenal insufficiency in meningococcal sepsis: bioavailable cortisol levels and impact of interleukin-6 levels and intubation with etomidate on adrenal function and mortality. J Clin Endocrinol Metab. 2005 Sep;90(9):5110-7. Epub 2005 Jun 28.</citation>
    <PMID>15985474</PMID>
  </reference>
  <reference>
    <citation>Absalom A, Pledger D, Kong A. Adrenocortical function in critically ill patients 24 h after a single dose of etomidate. Anaesthesia. 1999 Sep;54(9):861-7.</citation>
    <PMID>10460557</PMID>
  </reference>
  <reference>
    <citation>Annane D. ICU physicians should abandon the use of etomidate! Intensive Care Med. 2005 Mar;31(3):325-6. Epub 2005 Jan 27.</citation>
    <PMID>15750800</PMID>
  </reference>
  <reference>
    <citation>Duthie DJ, Fraser R, Nimmo WS. Effect of induction of anaesthesia with etomidate on corticosteroid synthesis in man. Br J Anaesth. 1985 Feb;57(2):156-9.</citation>
    <PMID>2982387</PMID>
  </reference>
  <reference>
    <citation>Fellows IW, Bastow MD, Byrne AJ, Allison SP. Adrenocortical suppression in multiply injured patients: a complication of etomidate treatment. Br Med J (Clin Res Ed). 1983 Dec 17;287(6408):1835-7.</citation>
    <PMID>6322902</PMID>
  </reference>
  <reference>
    <citation>Fellows IW, Byrne AJ, Allison SP. Adrenocortical suppression with etomidate. Lancet. 1983 Jul 2;2(8340):54-5.</citation>
    <PMID>6134923</PMID>
  </reference>
  <reference>
    <citation>Wagner RL, White PF, Kan PB, Rosenthal MH, Feldman D. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med. 1984 May 31;310(22):1415-21.</citation>
    <PMID>6325910</PMID>
  </reference>
  <reference>
    <citation>Allolio B, Stuttmann R, Fischer H, Leonhard W, Winkelmann W. Long-term etomidate and adrenocortical suppression. Lancet. 1983 Sep 10;2(8350):626.</citation>
    <PMID>6136774</PMID>
  </reference>
  <reference>
    <citation>Crozier TA, Beck D, Wuttke W, Kettler D. [Relation of the inhibition of cortisol synthesis in vivo to plasma etomidate concentrations]. Anaesthesist. 1988 May;37(5):337-9. German.</citation>
    <PMID>3261141</PMID>
  </reference>
  <reference>
    <citation>Watt I, Ledingham IM. Mortality amongst multiple trauma patients admitted to an intensive therapy unit. Anaesthesia. 1984 Oct;39(10):973-81.</citation>
    <PMID>6496912</PMID>
  </reference>
  <reference>
    <citation>Kenyon CJ, McNeil LM, Fraser R. Comparison of the effects of etomidate, thiopentone and propofol on cortisol synthesis. Br J Anaesth. 1985 May;57(5):509-11.</citation>
    <PMID>2986663</PMID>
  </reference>
  <reference>
    <citation>Kilger E, Weis F, Briegel J, Frey L, Goetz AE, Reuter D, Nagy A, Schuetz A, Lamm P, Knoll A, Peter K. Stress doses of hydrocortisone reduce severe systemic inflammatory response syndrome and improve early outcome in a risk group of patients after cardiac surgery. Crit Care Med. 2003 Apr;31(4):1068-74.</citation>
    <PMID>12682474</PMID>
  </reference>
  <reference>
    <citation>Loisa P, Uusaro A, Ruokonen E. A single adrenocorticotropic hormone stimulation test does not reveal adrenal insufficiency in septic shock. Anesth Analg. 2005 Dec;101(6):1792-8.</citation>
    <PMID>16301260</PMID>
  </reference>
  <reference>
    <citation>Neumann R, Worek FS, Blümel G, Zimmermann GJ, Fehm HL, Pfeiffer UJ. Cortisol deficiency in metomidate anesthetized bacteremic pigs: results in circulatory failure--beneficial effect of cortisol substitution. Acta Anaesthesiol Scand. 1989 Jul;33(5):379-84.</citation>
    <PMID>2572134</PMID>
  </reference>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2006</study_first_submitted>
  <study_first_submitted_qc>December 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2006</study_first_posted>
  <last_update_submitted>March 3, 2010</last_update_submitted>
  <last_update_submitted_qc>March 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Stefan M Jakob, Professor</name_title>
    <organization>Department of Critical Care Medicine</organization>
  </responsible_party>
  <keyword>Etomidate</keyword>
  <keyword>Propofol</keyword>
  <keyword>Adrenocortical Insufficiency</keyword>
  <keyword>Hemodynamic Process</keyword>
  <keyword>Vasoactive Agonists</keyword>
  <keyword>Coronary Artery Bypass</keyword>
  <keyword>Ischemic Coronary Heart Disease</keyword>
  <keyword>Mitral valve reconstruction/replacement</keyword>
  <keyword>Mitral valve regurgitation</keyword>
  <keyword>Heart Valve Prosthesis</keyword>
  <keyword>Cardiopulmonary Bypass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Etomidate</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Cosyntropin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

